The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer
Purpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism o...
Saved in:
Main Authors: | Diomidis Kozyrakis, Dionyssios Paridis, Stefanos Perikleous, Konstantinos Malizos, Anastasios Zarkadas, Antonios Tsagkalis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Advances in Urology |
Online Access: | http://dx.doi.org/10.1155/2018/1525832 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01) -
Role of CXCL10 released from osteocytes in response to TNF-α stimulation on osteoclasts
by: Mariko Miura, et al.
Published: (2025-01-01) -
The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges
by: Daniel W. Smith, et al.
Published: (2012-01-01) -
Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
by: Jennifer N. Wu, et al.
Published: (2010-01-01) -
Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)